FDA To Review Experimental Gene Therapy To Treat Childhood Blindness

Oct 12, 2017
Originally published on October 12, 2017 3:22 pm

A panel of experts will advise the Federal and Drug Administration on Thursday on whether to approve Luxturna, a one-time shot that would repair a defective gene that causes inherited child blindness. If approved, it would be the first legal gene therapy on the market in the U.S.

Here & Now‘s Lisa Mullins discusses with Adam Feuerstein (@adamfeuerstein), national biotech columnist for the health and medicine publication STAT.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.